551 - 560 of 690 Results

  • Kaiser Health Tracking Poll: September 2013

    Feature

    September 2013 Kaiser Health Tracking Poll gauges public opinion on the ACA days before open enrollment for Obamacare health insurance marketplaces begins.

  • Health Reform: Implications for Women’s Access to Coverage and Care

    Issue Brief

    This issue brief, Health Reform: Implications for Women's Access to Coverage and Care, reviews how the Affordable Care Act is expected to affect access to care and affordability of health coverage for women. It also explains the provisions in the health reform law related to preventive screening services, reproductive health, maternity care and women on Medicare. The brief includes national and state-level estimates of the percentage of uninsured women ages 18-64 who are likely to qualify for federal help under the law and a summary of key coverage and benefits provisions in the health reform law that affect women.

  • Quantifying Tax Credits for People Now Buying Insurance on Their Own

    Issue Brief

    This analysis estimates that Americans currently buying insurance on the individual market would receive $2700 in subsidies (as tax credits) in 2014 under Obamacare. Tax credits are available for qualifying people buying insurance through the new health care marketplaces, or exchanges.

  • To Switch or Not to Switch: Are Medicare Beneficiaries Switching Drug Plans To Save Money?

    Issue Brief

    This analysis finds that relatively few Medicare beneficiaries have switched Part D prescription drug plans voluntarily during the annual open enrollment period -- even though those who do switch often lower their out-of-pocket costs as a result of changing plans. The vast majority (87% on average between 2006 and 2010) stayed in the same Part D plan, even though the plans can change premiums, deductibles, cost-sharing amounts, and their list of covered drugs each year. Higher rates of plan switching were observed in PDPs that increased premiums, increased deductibles, or dropped coverage of brand-name drugs in the coverage gap.